Related Experiment Video

Updated: May 27, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

PDE4: a novel target in the treatment of chronic obstructive pulmonary disease

J M Michalski1, G Golden, J Ikari

  • 1Section of Pulmonary, Critical Care, Sleep and Allergy, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. jmichalski@unmc.edu

Clinical Pharmacology and Therapeutics
|December 2, 2011
PubMed

Insights

Phosphodiesterases (PDEs) regulate inflammation and healing. Inhibiting PDE4 offers a promising, targeted approach for improving chronic obstructive pulmonary disease (COPD) treatment outcomes.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Respiratory Medicine

Background:

  • Phosphodiesterases (PDEs) play a crucial role in modulating inflammatory processes and tissue repair.
  • Chronic obstructive pulmonary disease (COPD) treatment remains suboptimal, highlighting the need for novel therapeutic strategies.
  • PDE4 is a key enzyme involved in regulating the inflammatory response within the lung.

Purpose of the Study:

  • To review the current status of phosphodiesterase 4 (PDE4) inhibitor therapy for the treatment of COPD.
  • To explore the potential of PDE4 inhibition as a COPD-specific therapeutic strategy.

Main Methods:

  • Literature review of existing studies on PDE4 inhibitors and their application in COPD.
  • Analysis of the role of PDE4 in the pathogenesis of COPD-related lung inflammation.

Main Results:

  • PDE4 inhibition demonstrates potential for modulating the lung's inflammatory response in COPD.
  • Targeting PDE4 represents a novel, disease-specific therapeutic avenue for COPD management.

Conclusions:

  • PDE4 inhibitors are a developing therapeutic class for COPD.
  • Further research and clinical trials are warranted to fully establish the efficacy and safety of PDE4 inhibitors in COPD treatment.

More Related Videos

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...